Dechra Pharmaceuticals PLC (LON:DPH – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,877.09 ($36.30) and traded as high as GBX 3,704 ($46.74). Dechra Pharmaceuticals shares last traded at GBX 3,666 ($46.26), with a volume of 514,195 shares traded.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Berenberg Bank restated a “hold” rating and issued a GBX 2,850 ($35.96) price target on shares of Dechra Pharmaceuticals in a research report on Monday, February 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 3,112 ($39.27) price objective on shares of Dechra Pharmaceuticals in a research note on Tuesday, February 28th. Finally, JPMorgan Chase & Co. dropped their price objective on Dechra Pharmaceuticals from GBX 4,600 ($58.04) to GBX 4,000 ($50.47) and set an “overweight” rating for the company in a research note on Tuesday, March 7th.
Dechra Pharmaceuticals Price Performance
The company has a current ratio of 2.73, a quick ratio of 1.66 and a debt-to-equity ratio of 60.73. The stock has a market cap of £4.24 billion, a price-to-earnings ratio of 10,474.29, a PEG ratio of 1.42 and a beta of 0.71. The stock has a 50-day moving average price of GBX 3,031.22 and a two-hundred day moving average price of GBX 2,877.09.
Dechra Pharmaceuticals Cuts Dividend
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.